Sign up to receive Dana-Farber Spotlight, our email newsletter.View the current issueSubscribe nowUnsubscribe from mailings
Ellen BerlinDirector of Media Relations617firstname.lastname@example.org
Molly McHaleAssociate Director of Media Relations617email@example.com
Dr. Toni Choueiri led a study that found patients with non–clear cell renal cell carcinoma, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Dr. Harold Burstein commented on a study that found there was no evidence that surgery lowered the risk of death compared to more conservative lumpectomy and radiation.
Shannon Harrington, PhD, participated in a study showing a patient's race and ethnicity dramatically influenced their preferences about the care they receive at the end of their lives.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: